
Recent advances in cytokines: Therapeutic implications for inflammatory bowel diseases
Author(s) -
Guillaume Bouguen,
Jean–Baptiste Chevaux,
Laurent PeyrinBiroulet
Publication year - 2011
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v17.i5.547
Subject(s) - immune system , immunology , inflammation , medicine , proinflammatory cytokine , inflammatory bowel disease , acquired immune system , inflammatory bowel diseases , innate immune system , disease , pathology
Inflammatory bowel diseases (IBDs) are complex and chronic disabling conditions resulting from a dysregulated dialogue between intestinal microbiota and components of both the innate and adaptive immune systems. Cytokines are essential mediators between activated immune and non-immune cells, including epithelial and mesenchymal cells. They are immunomodulatory peptides released by numerous cells and these have significant effects on immune function leading to the differentiation and survival of T cells. The physiology of IBD is becoming a very attractive field of research for development of new therapeutic agents. These include cytokines involved in intestinal immune inflammation. This review will focus on mechanisms of action of cytokines involved in IBD and new therapeutic opportunities for these diseases.